Mutated neo-antigens in hepatocellular carcinoma

Project Details

Description

The primary objective is to evaluate genetically modified epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model.
Specific goals: Identification of specific, genetically modified antigens of hepatocellular carcinoma using new generation sequencing and evaluation of specific T cell response in vitro, before and after therapy.
Evaluation of genetically altered epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model.
Identification of protein-specific, genetically modified cell-surface specific full-length hepatocellular carcinoma cells and immune evaluation in vivo.
The main activities:
Identification of mutant neoantigens in liver carcinoma of different aetiology and assessment of in vitro T cell specific response after treatment with cell cycle inhibitors.
Identification of selected mutant epitopes in vivo using HLA transgenic mice and their therapeutic effect in a HCC-PDX animal model.
AcronymHEPAMUT
StatusFinished
Effective start/end date20/02/1719/02/20

Funding

  • European Commission: €1,109,900.00

Keywords

  • liver cancer
  • mutated human tumor antigenic targets
  • omics approaches
  • immunulogical validation ex vivo and in vivo
  • development of HCC-PDX animal models
  • immune checkpoint inhibit

Smart Specialization Area

  • Biomedicine, medical technologies and biotechnology

Field of Science

  • 3.3 Health sciences